Iksuda Therapeutics

Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat solid and haematological cancers.

Its ADC platform combines proprietary stable bioconjugation chemistry with tumour-selective payload activation to improve therapeutic index.

The company's lead candidate, IKS014, is a HER2-targeting ADC in Phase 1 clinical trials. Iksuda also develops novel payload classes including its first-in-class protein alkylating agents.

The company operates from Newcastle Helix with additional facilities in the United States.